Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sean M Murphy

Showing results (111-120 of 176) with videos related to

Pageof 18
Sort By:
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|February 24, 2024
Economic Evaluations of Establishing Opioid Overdose Prevention Centers in 12 North American Cities: A Systematic ReviewCzarina N Behrends, Jared A Leff, Weston Lowry, et al.
The American Journal of Emergency Medicine|August 27, 2025
Microcosting implementation facilitation for emergency department-initiated buprenorphine for untreated opioid use disorderDanielle Ryan, Thanh Lu, E Jennifer Edelman, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 17, 2019
Cost-effectiveness of Hepatitis C Virus Treatment Models for People Who Inject Drugs in Opioid Agonist Treatment ProgramsSarah Gutkind, Bruce R Schackman, Jake R Morgan, et al.
Drug and Alcohol Dependence|December 3, 2022
Telemedicine along the cascade of care for substance use disorders during the COVID-19 pandemic in the United StatesChunqing Lin, Huyen Pham, Yuhui Zhu, et al.
Contemporary Clinical Trials|April 23, 2018
Using a randomized controlled trial to test whether modifications to contingency management improve outcomes for heavy drinkers with serious mental illnessOladunni Oluwoye, Jordan Skalisky, Ekaterina Burduli, et al.
Experimental and Clinical Psychopharmacology|August 28, 2018
Predictors of tobacco and alcohol co-use from ages 15 to 32: The Amsterdam Growth and Health Longitudinal StudySterling M McPherson, Ekaterina Burduli, Crystal Lederhos Smith, et al.
Addiction (Abingdon, England)|May 5, 2021
Cost-effectiveness implications of increasing the efficiency of the extended-release naltrexone induction process for the treatment of opioid use disorder: a secondary analysisSean M Murphy, Philip J Jeng, Kathryn E McCollister, et al.
Addiction (Abingdon, England)|March 22, 2022
Population-level impact of initiating pharmacotherapy and linking to care people with opioid use disorder at inpatient medically managed withdrawal programs: an effectiveness and cost-effectiveness analysisAlexandra Savinkina, Rajapaksha W M A Madushani, Golnaz Eftekhari Yazdi, et al.
Journal of Substance Abuse Treatment|February 26, 2017
Do patient characteristics moderate the effect of extended-release naltrexone (XR-NTX) for opioid use disorder?Peter D Friedmann, Donna Wilson, Edward V Nunes, et al.
The International Journal on Drug Policy|September 5, 2021
Targeting community-based naloxone distribution using opioid overdose death rates: A descriptive analysis of naloxone rescue kits and opioid overdose deaths in Massachusetts and Rhode IslandXiao Zang, Alexandria Macmadu, Maxwell S Krieger, et al.
Pageof 18

Showing results (111-120 of 176) with videos related to

Sort By:
Pageof 18
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|February 24, 2024
Economic Evaluations of Establishing Opioid Overdose Prevention Centers in 12 North American Cities: A Systematic ReviewCzarina N Behrends, Jared A Leff, Weston Lowry, et al.
The American Journal of Emergency Medicine|August 27, 2025
Microcosting implementation facilitation for emergency department-initiated buprenorphine for untreated opioid use disorderDanielle Ryan, Thanh Lu, E Jennifer Edelman, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 17, 2019
Cost-effectiveness of Hepatitis C Virus Treatment Models for People Who Inject Drugs in Opioid Agonist Treatment ProgramsSarah Gutkind, Bruce R Schackman, Jake R Morgan, et al.
Drug and Alcohol Dependence|December 3, 2022
Telemedicine along the cascade of care for substance use disorders during the COVID-19 pandemic in the United StatesChunqing Lin, Huyen Pham, Yuhui Zhu, et al.
Contemporary Clinical Trials|April 23, 2018
Using a randomized controlled trial to test whether modifications to contingency management improve outcomes for heavy drinkers with serious mental illnessOladunni Oluwoye, Jordan Skalisky, Ekaterina Burduli, et al.
Experimental and Clinical Psychopharmacology|August 28, 2018
Predictors of tobacco and alcohol co-use from ages 15 to 32: The Amsterdam Growth and Health Longitudinal StudySterling M McPherson, Ekaterina Burduli, Crystal Lederhos Smith, et al.
Addiction (Abingdon, England)|May 5, 2021
Cost-effectiveness implications of increasing the efficiency of the extended-release naltrexone induction process for the treatment of opioid use disorder: a secondary analysisSean M Murphy, Philip J Jeng, Kathryn E McCollister, et al.
Addiction (Abingdon, England)|March 22, 2022
Population-level impact of initiating pharmacotherapy and linking to care people with opioid use disorder at inpatient medically managed withdrawal programs: an effectiveness and cost-effectiveness analysisAlexandra Savinkina, Rajapaksha W M A Madushani, Golnaz Eftekhari Yazdi, et al.
Journal of Substance Abuse Treatment|February 26, 2017
Do patient characteristics moderate the effect of extended-release naltrexone (XR-NTX) for opioid use disorder?Peter D Friedmann, Donna Wilson, Edward V Nunes, et al.
The International Journal on Drug Policy|September 5, 2021
Targeting community-based naloxone distribution using opioid overdose death rates: A descriptive analysis of naloxone rescue kits and opioid overdose deaths in Massachusetts and Rhode IslandXiao Zang, Alexandria Macmadu, Maxwell S Krieger, et al.
Pageof 18